135159-51-2 Usage
Description
Sarpogrelate hydrochloride is a potent and selective serotonin 5-HT2 receptor antagonist that was launched in Japan as an antithrombotic. It exhibits inhibition of ex vivo platelet aggregation stimulated by serotonin in combination with collagen and suppression of blood vessel constriction mediated by 5-HT2 in vitro. Sarpogrelate hydrochloride is a white solid and is available under the brand name Anplag.
Uses
Used in Pharmaceutical Industry:
Sarpogrelate hydrochloride is used as an antithrombotic agent for its ability to inhibit platelet aggregation and blood vessel constriction, making it particularly useful for patients with Type 2 diabetes mellitus.
Used in Cardiovascular Applications:
Sarpogrelate hydrochloride is used as an antiplatelet agent to reduce the risk of arterial thrombosis and peripheral obstructive disease, as well as to decrease ventricular hypertrophy and infarct size in a rat model of myocardial infarction.
Used in Research and Development:
Sarpogrelate hydrochloride is used as a selective antagonist of the serotonin (5-HT) receptor subtypes 5-HT2A, 5-HT2B, and 5-HT2C for studying the role of these receptors in various biological processes and developing new therapeutic strategies.
Originator
Mitsubishi Kasei (Japan
)
Biological Activity
Selective 5-HT 2A receptor antagonist (pK i values are 8.52, 7.43 and 6.57 for 5-HT 2A , 5-HT 2C and 5-HT 2B receptors respectively). Displays selectivity over 5-HT 1 , 5-HT 3 , 5-HT 4 H 1 , H 2 , M 3 , α 1 -adrenergic, α 2 -adrenergic and β -adrenergic receptors. Displays cardioprotective activity in vivo .
in vitro
the major metabolite (r,s)-m-1, and m-1 enantiomers of sarpogrelate specifically blocked 5-ht at 5-ht2a receptors. the stereochemical configuration of the ligands does not obviously play a key role at binding to the 5-ht2a receptor [2].
in vivo
pad patients were divided into two groups. one group treated with 100 mg sarpogrelate in oral 3 times one day for 12 weeks (n = 10), while the other group who remained on conventional therapy as control group (n = 11). forearm blood flow (fbf) and leg blood flow (lbf) responses to reactive hyperemia (rh) and sublingual administration of nitroglycerin (ntg) were measured by strain-gauge plethysmography. after twelve weeks of its administration, fbf and lbf responses during rh exhibited significant increases from 13.2 6 1.7 to 18.1 6 2.2 ml/min every 100 ml tissue (p , 0.01) and from 8.2 6 0.9 to 14.2 6 2.1 ml/min every 100 ml tissue (p , 0.05), respectively. augmentation of fbf and lbf induced by sarpogrelate responses to rh was maintained at 24 weeks. the control group had no change observed in at each follow-up time point. the changes in fbf and lbf after sublingual ntg were similar during follow-up periods in the two groups. these findings suggest that longterm oral administration of sarpogrelate improves vascular function in patients with pad [3].
references
[1] nishio h1, inoue a, nakata y. binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes. arch int pharmacodyn ther. 1996 mar-apr;331(2):189-202.[2] pertz h1, elz s. in-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-ht2a receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-ht contractions in rat tail artery. j pharm pharmacol. 1995 apr;47(4):310-6.[3] miyazaki m1, higashi y, goto c, chayama k, yoshizumi m, sanada h, orihashi k, sueda t. sarpogrelate hydrochloride, a selective 5-ht2a antagonist, improves vascular function in patients with peripheral arterial disease. j cardiovasc pharmacol. 2007 apr;49(4):221-7.
Check Digit Verification of cas no
The CAS Registry Mumber 135159-51-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,1,5 and 9 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 135159-51:
(8*1)+(7*3)+(6*5)+(5*1)+(4*5)+(3*9)+(2*5)+(1*1)=122
122 % 10 = 2
So 135159-51-2 is a valid CAS Registry Number.
InChI:InChI=1/C24H31NO6.ClH/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3;/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27);1H
135159-51-2Relevant articles and documents
METHODS FOR PREPARING SARPOGRELATE HYDROCHLORIDE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
Paragraph 0084; 0086-0090; 0158, (2020/10/20)
The present invention provides hydrochloride salt hydrochloride. More specifically, the present invention relates to a method for preparing a hydrochloride salt having high purity and less toxicity in the body, and a pharmaceutical formulation comprising the same. The present invention relates to a hydrochloride and a pharmaceutical composition containing the same, and to a pharmaceutical composition containing the same, and a pharmaceutical composition containing the same, and a pharmaceutical composition containing the same. (by machine translation)
Process for preparing sand Greythe ester is new hydrochloric acid
-
Paragraph 0019; 0023; 0027, (2018/07/10)
The present invention discloses a preparation method of sarpogrelate hydrochloride. According to the preparation method, 2-[2-(3-methoxyphenyl)ethyl]phenol is adopted as a starting reactant, benzyl triethylammonium chloride is adopted as a phase transfer catalyst, the starting reactant, the phase transfer catalyst and epichlorohydrin form an ether in toluene and water, dimethylamine is adopted to carry out aminolysis in a pressurization reactor after the ether is formed to obtain 1-dimethylamino-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-2-propanol, the 1-dimethylamino-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-2-propanol and succinic anhydride are subjected to esterification in acetone, hydrogen chloride gas is directly introduced without recovery and replacement of the solvent to form a hydrochloride, and re-crystallization with acetone is performed to obtain the sarpogrelate hydrochloride refined product, wherein the purity is more than 99%.
Pharmaceutically active (3-aminopropoxy)bibenzyl derivatives
-
, (2008/06/13)
(3-Aminopropoxy)bibenzyl derivatives are prepared and found useful as pharmaceutical agents, particularly as inhibitors of platelet aggregation.
